Rheumatoid arthritis: an overview of new and emerging therapies (Q36160669)

12 August 2017

1 reference

title

Rheumatoid arthritis: an overview of new and emerging therapies (English)

1 reference

12 August 2017

0 references

Tanya Doan

1

1 reference

PubMed ID

15951465

12 August 2017

Elena Massarotti

series ordinal

2

1 reference

12 August 2017

1 July 2005

1 reference

The Journal of Clinical Pharmacology

12 August 2017

1 reference

12 August 2017

45

1 reference

12 August 2017

7

1 reference

12 August 2017

751-762

1 reference

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

12 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Rheumatoid arthritis--a molecular understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Glucocorticoids in the treatment of early and late RA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Auranofin versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Long-term effectiveness of antimalarial drugs in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Hydroxychloroquine and visual screening in a rheumatology outpatient clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Methotrexate use in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Infectious complications of treatment with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

New drugs for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

A lupus-like syndrome associated with infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Pharmacokinetics of anakinra in subjects with different levels of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

Neuroendocrine immune mechanisms in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277938

21 January 2018

Identifiers

DOI

10.1177/0091270005277938

1 reference

12 August 2017

1 reference

PubMed ID

15951465